---
title: "4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293220697.md"
description: "4D Molecular Therapeutics reported positive two-year Phase 2b data for its one-shot eye therapy, 4D-150, in wet AMD. The treatment reduced patient treatment burden by up to 87% compared to standard care, with consistent visual acuity maintenance and a favorable safety profile. The company has completed enrollment in two Phase 3 trials (4FRONT-1 and 4FRONT-2), with top-line data expected in 2027. Analysts at HC Wainwright reiterated a Buy rating with a $36 price target."
datetime: "2026-07-20T13:05:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293220697.md)
  - [en](https://longbridge.com/en/news/293220697.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293220697.md)
generator: "portal-rs"
---

# 4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win

On Saturday, **4D Molecular Therapeutics Inc.** (NASDAQ:FDMT), a late-stage biotechnology firm focused on disease-targeted therapeutics, shared two-year results from its PRISM Phase 2b trial of 4D-150 in a broad wet age-related macular degeneration population.

## Key Efficacy Outcomes Through Two Years

The Phase 2b study evaluated a single intravitreal dose of 4D-150 across two dosage levels, 3E10 vg/eye and 1E10 vg/eye, enrolling 45 total patients.

The 3E10 vg/eye level was selected as the designated dose for the upcoming 4FRONT Phase 3 trials.

Within the broad study group, 30 patients received the 3E10 vg/eye dose, while 15 received the lower dose.

A subgroup of 15 recently diagnosed patients—those diagnosed within six months—also received the 3E10 vg/eye dose to align with the Phase 3 trial target population.

As of the May 18, 2026, data cutoff, treatment with 4D-150 demonstrated consistent maintenance of best corrected visual acuity and steady control of central subfield thickness.

Patients experienced a meaningful, long-term drop in treatment burden across two years, maintaining a clear dose response in favor of the Phase 3 dosage.

 **Read Also: Outlook Therapeutics Eye Drug Review Returns To FDA For Fourth Time** 

## Substantial Reductions In Patient Treatment Burden

Overall, trial participants achieved a 78% reduction in overall treatment burden, averaging 2.7 supplemental injections compared to the projected 12.0 injections for on-label aflibercept 2 mg administered every eight weeks.

The recently diagnosed subgroup demonstrated an even greater 87% reduction in treatment burden, averaging 1.6 supplemental injections per patient.

## Safety And Tolerability Profile

Safety data covering 71 patients across Phase 1/2a and 2b trials at the Phase 3 dose showed 4D-150 was well tolerated.

Only 2.8% of patients (two individuals) experienced mild, transient intraocular inflammation within the first 28 weeks post-dosing.

Beyond 28 weeks, no new cases of inflammation were observed with two to over four years of follow-up.

Furthermore, no cases of hypotony, endophthalmitis, vasculitis, retinal vasculitis, or choroidal effusions were recorded.

In February, 4D Molecular Therapeutics completed enrollment in the 4FRONT-1 Phase 3 trial of 4D-150 for wet age-related macular degeneration (wet AMD), with topline data expected in the first half of 2027.

In June, the company completed enrollment in 4FRONT-2, the second Phase 3 trial in the global program evaluating 4D-150. Topline data is expected in the second half of 2027.

On Monday, **HC Wainwright & Co.** analyst Matthew Caufield reiterated 4D Molecular with a Buy and maintains $36 price forecast.

**FDMT Stock Price Activity**: 4D Molecular Therapeutics shares were up 2.82% at $11.30 during premarket trading on Monday, according to Benzinga Pro data.

*Image via Shutterstock*

 **Read Also: Domino's CEO Says Growth Story Is 'As Strong As Ever'**

### Related Stocks

- [FDMT.US](https://longbridge.com/en/quote/FDMT.US.md)
- [OTLK.US](https://longbridge.com/en/quote/OTLK.US.md)
- [DPZ.US](https://longbridge.com/en/quote/DPZ.US.md)

## Related News & Research

- [4D Molecular Therapeutics Chief Legal Officer Scott Bizily disposes of 584 common shares for $8,176](https://longbridge.com/en/news/297965693.md)
- [4D Molecular Therapeutics posts corporate presentation highlighting AAV gene therapy pipeline led by 4D-150 for wet AMD, DME](https://longbridge.com/en/news/296635019.md)
- [BYD Launches Sealion 08, Starts Mass Producing 4D Radar Chip](https://longbridge.com/en/news/297856729.md)
- [HaemaLogiX doses first patient with KMCAR T-cell in KOALA trial](https://longbridge.com/en/news/298029912.md)
- [The Wizard of Oz at Sphere Unveils New & Expanded 4D Effects | SPHR Stock News](https://longbridge.com/en/news/297552836.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**